GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Novo Nordisk

Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably.

The 3 Most Undervalued Pharma Stocks to Buy in June 2024

What was supposed to be a stellar day for GSK PLC (LSE:GSK, NYSE:GSK) at the annual American Society of Clinical Oncology turned into quite the opposite. News of an adverse ruling in a Delaware court affecting long-running litigation over Zantac, the heartburn tablet linked cancer, overshadowed what was a very bullish read-out from a trial of its Blenrep drug in people suffering multiple myeloma.

GSK: Still reasons to be cheerful rather than fearful after 'nightmare' Monday

Many investors expected today's move in GlaxoSmithKline (NYSE: GSK ), with shares of GSK stock plunging more than 8% in early afternoon trading. That's because, on Friday, a Delaware judge ruled that expert witnesses would be allowed to testify in court that the company's discontinued Zantac heartburn medication may have caused cancer.

GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.

American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the drugmaker's discontinued heartburn treatment, Zantac, causes cancer can go forward.

GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward

GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.

GSK Stock Dips on Delaware Court Ruling for Zantac Litigation

GSK plc (NYSE:GSK) faced a significant setback on June 3rd when its stock plunged by 8% following a Delaware judge's ruling allowing over 70,000 lawsuits against the company regarding its discontinued heartburn drug Zantac to proceed.

Is GSK stock a sell with 75,000 Zantac cases moving forward?

GSK shares plunged Monday after the Delaware State Court ruled that expert witnesses can present scientific evidence in the roughly 75,000 cases relating to the discontinued heartburn drug Zantac. The drug was manufactured and sold by several companies from the 1980s until 2020, when it was recalled over concerns it contained a probable carcinogen called NDMA.

Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits

PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer.

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as it focused on the long-term potential of the stock. After hours on Friday, the Delaware Superior Court allowed over 70,000 lawsuits related to the heartburn drug to proceed, creating a significant overhang for the pharmaceutical giant.

GSK: Zantac litigation obscures the positives, says leading investment bank

GSK shares dropped 10% after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition. GSK said it's going to appeal the decision.

GSK shares tumble 10% after Zantac ruling

Shares in British drugmaker GSK dropped more than 9% on Monday after a Delaware judge allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward.

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward

GSK PLC (LSE:GSK, NYSE:GSK) says it disagrees with a decision by a court judge in the US state of Delaware who has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward. The ruling, from late on Friday by Judge Vivian Medinilla of the Delaware Superior Court, was that expert witnesses can testify in court that the drug may cause cancer.

GSK to appeal US judge's Zantac ruling

PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma.

Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday.

GSK blood cancer drug nearly halves risk of death in late-stage trial

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?

Deutsche Bank

GSK's development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma's top R&D executives. Work needs to be done to rebuild the innovation proposition in the eyes of many investors, but Deutsche Bank sees clear emergent strands of underappreciated potential.

GSK development pipeline underrated suggests Deutsche Bank

AstraZeneca

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.

AstraZeneca started at buy at Goldman, which rates GSK a neutral

On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 million, up 46.6% from the previous quarter. The company has a rich pipeline of investigational vaccines and drugs, many of which have the potential to become "gold standards" in the fight against various viruses and disorders.

GSK plc: Long-Term Cash Cow

British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois, US, over its heartburn medication Zantac. A jury determined that Zantac was not responsible for the plaintiff's colon cancer, with the judge rejecting a request for $640 million in damages.

GSK found not guilty in Zantac trial

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why GSK (GSK) is a Top Momentum Stock for the Long-Term

GSK's GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinical trials. Financially, GSK shows solid earnings growth but has a current ratio below 1, indicating possible liquidity issues.

GSK Breathes New Life Into Asthma Treatment With Depemokimab

GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.

GSK: Zantac settlement could reach $2bn, says investment bank

GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.

GSK says late-stage trials of potential blockbuster asthma drug met their goals

GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.

News for GlaxoSmithKline Stock (GSK)